Aktienanalyse zu argenx SE (ARGX)ARGXargenx SE

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications. It operates in the Healthcare sector.

Currently, Argenx SE (ARGX) is not a strong buy due to recent negative developments, including a 10.25% drop in the last five days and an RSI of 15.953, indicating oversold conditions. However, the average analyst price target of $1,182 suggests a potential upside of about 29% from the current price of $825.03, driven by strong sales growth and positive results from other trials. The main risk is the recent trial discontinuation, which has created uncertainty in the stock's immediate outlook.

5 analysts cover ARGX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 1,048.